TickerTalks
Browse all tickers →
TickerTalks›$IQV
IQIQV

IQVIA Holdings Inc.

$IQV·$28B·Medical - Diagnostics & Research·Healthcare
$185.76+8.5%YTD-20.5%1Y+12.5%
Mentions · last 7 days
2026-06-17: 10 posts2026-06-18: 6 posts2026-06-19: 1 posts2026-06-20: 0 posts2026-06-21: 1 posts2026-06-22: 2 posts2026-06-23: 4 posts24+5%
Price updated 11m ago·X counts updated 20h ago
IQIQV
$IQVIQVIA Holdings Inc.
$185.76+8.45%24 posts+5%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $IQV, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptWinding up for a moveAI verdict · as of 2026-06-23

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

IQVIA is -21% YTD despite four straight EPS beats — €950M senior-note issuance plus $2B buyback signal capital deployment for the rerating.

IQVIA Holdings is the global life-sciences clinical research, technology, and analytics provider — Technology & Analytics Solutions, R&D Solutions, Contract Sales & Medical Solutions. The setup is a turnaround coiling against operational stability and capital-return activation.

What's happening:

  • Earnings cadence is intact and beating: the last four quarters surprised by +2.8%, +0.6%, +0.7%, +1.4%, with Q1 revenue of $4.15B against the sequence ($4.02B → $4.10B → $4.36B → $4.15B) — gross margin variable, the EPS sequence ($1.55 → $1.94 → $3.02 → $1.63) reflects services-business seasonality but consistent meet-or-beats.
  • Capital-structure activation is the rerating thesis: the May 7 $2B share-repurchase authorization plus the June 11 €950M (~$1.04B) 4.625% senior unsecured notes due 2033 reflects deliberate capital deployment — the buyback is structurally meaningful at the depressed multiple.
  • M&A-wave and Healthcare-Infrastructure support the rerating: 'The Healthcare M&A Wave' (June 17) plus 'Global Healthcare Infrastructure Strengthens IQV' (June 15) frames institutional re-positioning — combined with the June 18 StackAdapt MediaOS partnership and the 'Top Value Stock' framing, the catalyst layer is firming.

-21% YTD, +13% TTM, $28B market cap. July 28 Q2 earnings is the test — EPS beat plus R&D Solutions backlog growth extends the rerating; clinical-trial-services slowdown or biopharma-capex downgrade cools. The $2B buyback is the structural anchor.

What to watch: July 28 Q2 earnings — Technology & Analytics Solutions growth, R&D Solutions backlog trajectory, EPS beat magnitude (must hold +1%+), $2B buyback execution detail, €950M senior-note deployment, StackAdapt MediaOS partnership progress, and biopharma-customer-capex commentary. EPS plus buyback extends; clinical-trial slowdown cools.

On the calendar: 2026-07-28 — Q2 2026 earnings

sentiment unavailable

Read the AI verdict + X sentiment for $IQV

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Provides healthcare data analytics, clinical trial management, and technology services to life sciences companies globally.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $IQV.

Medical - Diagnostics & Research · Healthcare

Life science instrument demand is normalizing after the post-COVID destocking cycle — pharma R&D spending is recovering and CDMO demand is growing as drug pipelines advance toward clinical trials. AI-assisted drug discovery (SDGR, TWST) is creating incremental instrument and data demand on top of the recovery cycle.

What this means for $IQV

Direct beneficiary — healthcare data analytics and clinical trial management for life sciences companies benefit from pharma pipeline activity growth; AI integration into clinical operations is an emerging pricing lever.

Industry benchmark

11-name peer basket
+5.9%YTD
+18.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
22.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
8.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
13.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
8.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
22.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
26.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 5, 2026$2.90$2.82+2.8%
Q4 2025Feb 5, 2026$3.42$3.40+0.6%
Q3 2025Oct 28, 2025$3.00$2.98+0.7%
Q2 2025Jul 22, 2025$2.81$2.77+1.4%
Next earningsTue, Jul 28·consensus EPS $3.03

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$4.2B+8.4%32.6%12.4%$1.63$618.0M
Q4 FY25$4.4B+10.3%6.7%16.8%$3.02$561.0M
Q3 FY25$4.1B+5.2%33.5%13.5%$1.94$1.2B
Q2 FY25$4.0B+5.3%32.9%12.6%$1.55$292.0M

Forward consensus

5-year forecast · up to 15 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$17.3B$17.2B – $17.4B$12.82$12.70 – $12.9215
FY27$18.3B$18.0B – $18.8B$14.16$13.62 – $14.7315
FY28$19.2B$19.2B – $19.3B$15.73$13.67 – $18.5414
FY29$20.4B$20.2B – $20.8B$17.88$17.68 – $18.339
FY30$21.4B$21.2B – $21.8B$20.30$20.06 – $20.8113

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.28%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+3.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-8.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 158.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.225-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 49 other (35 awards · 14 inkinds) in window

See when $IQV insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJun 118-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

IQVIA Inc. (a wholly owned subsidiary of IQVIA Holdings Inc.) completed the issuance of €950 million (~$1.04B) in 4.625% senior unsecured notes due June 15, 2033, on June 11, 2026. The notes are guaranteed by certain IQVIA subsidiaries; interest is payable semi-annually beginning December 15, 2026. Net proceeds will be used to refinance existing indebtedness and pay transaction fees. This is a euro-denominated refinancing that extends IQVIA's debt maturity profile at a moderate fixed rate, consistent with prior capital-structure management for a large healthcare data and analytics company.

8-KOfficer or director changeApr 238-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

IQV disclosed a personnel change (8-K Item 5.02, dated 2026-04-23). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

3New insider — initial holdingsJan 93
3New insider — initial holdingsJan 93
3New insider — initial holdingsJan 93
3New insider — initial holdingsJan 93
+ 13 other (3 routine 8-Ks · 2 earnings 8-Ks · 2 13Gs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

StackAdapt Teams Up with IQVIA Digital's MediaOS to Power Healthcare Advertisingbusinesswire.com·6d agoThe Healthcare M&A Waveforbes.com·7d agoWhy IQVIA Holdings (IQV) is a Top Value Stock for the Long-Termzacks.com·7d agoHere Are Wednesday's Best Wall Street Analyst Research Calls: Block, Charles River Laboratories, Cognizant Technology, Constellation Energy, Credicorp, First Solar, GE Vernova, Huntsman, Macerich, and More247wallst.com·7d agoGlobal Healthcare Infrastructure Strengthens IQV Amid Weak Liquidityzacks.com·9d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight LossAI Precision Medicine

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ATLN$A$GH$TWST$DHR$TMO$NTRA$ICLR
Voices on X · last 7 days

No standout posts about $IQV on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport